GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (NAS:OPNT) » Definitions » Interest Coverage

Opiant Pharmaceuticals (Opiant Pharmaceuticals) Interest Coverage : 0 (At Loss) (As of Sep. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Opiant Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Opiant Pharmaceuticals's Operating Income for the three months ended in Sep. 2022 was $-9.63 Mil. Opiant Pharmaceuticals's Interest Expense for the three months ended in Sep. 2022 was $-0.39 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Opiant Pharmaceuticals's Interest Coverage or its related term are showing as below:


OPNT's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 127.155
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Opiant Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Opiant Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Opiant Pharmaceuticals Interest Coverage Chart

Opiant Pharmaceuticals Annual Data
Trend Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20 Dec21
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,773.25 No Debt N/A - 2.42

Opiant Pharmaceuticals Quarterly Data
Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.24 2.53 - - -

Competitive Comparison of Opiant Pharmaceuticals's Interest Coverage

For the Biotechnology subindustry, Opiant Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opiant Pharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's Interest Coverage falls into.



Opiant Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Opiant Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2021 is calculated as

Here, for the fiscal year that ended in Dec. 2021, Opiant Pharmaceuticals's Interest Expense was $-2.13 Mil. Its Operating Income was $5.16 Mil. And its Long-Term Debt & Capital Lease Obligation was $16.74 Mil.

Interest Coverage=-1* Operating Income (A: Dec. 2021 )/Interest Expense (A: Dec. 2021 )
=-1*5.156/-2.129
=2.42

Opiant Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2022 is calculated as

Here, for the three months ended in Sep. 2022, Opiant Pharmaceuticals's Interest Expense was $-0.39 Mil. Its Operating Income was $-9.63 Mil. And its Long-Term Debt & Capital Lease Obligation was $14.41 Mil.

Opiant Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Opiant Pharmaceuticals  (NAS:OPNT) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Opiant Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals (Opiant Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.
Executives
David D O'toole officer: Chief Financial Officer 1640 MARENGO STREET, LOS ANGELES CA 90033
Ellison Mark Jason Heath other: UK Managing Director C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401
Roger Crystal director, 10 percent owner, officer: Chief Executive Officer 445 PARK AVE, 10TH FL., NEW YORK NY 10022
Phil Skolnick officer: Chief Scientific Officer C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601
Brian Gorman other: General Counsel 233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401
Matthew R. Ruth officer: Chief Commercial Officer 233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401
Michael Sinclair director, 10 percent owner, officer: Executive Chairman 86 GLOUCESTER PLACE, LONDON XX W1U6HP
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Ann L. Macdougall director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Thomas T. Thomas director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Masuoka K. Lorianne director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Gabrielle Alison Silver director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Rahsaan Thompson other: General Counsel 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Aziz Mottiwala officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Richard J Daly director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134

Opiant Pharmaceuticals (Opiant Pharmaceuticals) Headlines

From GuruFocus